TAHO PHARMACEUTICALS LTD.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
1. TAH4411 Ondansetron ODF
2. TAH3311 Apixaban Oral Film
3. TAH3341 Apixaban Oral Extend Release Film
4. TAH2211 Buprenorphine/Naloxone Sublingual Film
5. TAH2231 Naloxone Buccal Film
6. TAH9922 Atomoxetine Oral Liquid
7. TAH9901 Methylphenidate Patch
2. TAH3311 Apixaban Oral Film
3. TAH3341 Apixaban Oral Extend Release Film
4. TAH2211 Buprenorphine/Naloxone Sublingual Film
5. TAH2231 Naloxone Buccal Film
6. TAH9922 Atomoxetine Oral Liquid
7. TAH9901 Methylphenidate Patch
Founded Year
2010
Unified Business No.
25144594
Status
Active
Number of Employees
10
Total Paid-in
Capital
523,711,150 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2024)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
TAHO is a commercial-stage specialty pharma pioneering in oral, transdermal drug delivery systems. Collaborating with our partners across three continents, our pipeline of medicines targets CNS, Geriatric, and Pediatric therapies that provide caregivers with significant treatment options. From concept to commercial, we have several products launched in major markets. Trusted by partner pharma, we devote toward partner value and innovation.
